Literature DB >> 23904860

Pathogenic mechanisms linking benign prostatic hyperplasia, lower urinary tract symptoms and erectile dysfunction.

Sidney Glina1, Felipe Placco Araujo Glina.   

Abstract

INTRODUCTION: Erectile dysfunction (ED) and lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH) are clinical entities very prevalent in men aged over 50 years. There is evidence that both may have a common pathophysiology.
OBJECTIVE: The objective of this study was to conduct a literature review aiming to show theories and hypotheses that justify a single pathophysiology for ED and LUTS/BPH.
METHODS: A search in Medline using the keywords of the Medical Subject Headings (MESH) 'erectile dysfunction' and 'lower urinary tract symptoms' in all fields of the database up to 15 December 2012. This search found 198 relevant articles that were analyzed.
RESULTS: The data and articles were divided according to the type of evidence found. There are strong epidemiological data showing that LUTS/BPH is a risk factor for developing ED. Several experimental models demonstrated partial obstruction of the bladder in animals causes voiding disorders as well as a negative impact on erectile function of the operated animals. The increased adrenergic tonus in animals leads to prostate growth and urodynamic conditions similar to those found in men with LUTS and ED. Arteriosclerosis may lead to loss of vesical complacency, urinary tract obstruction and fibrosis of the cavernous bodies. The use of phosphodiesterase type 5 inhibitors (PDE-5i) and/or alpha-adrenergic blockers to treat ED and LUTS/BPH reinforces the hypothesis that, at least in some patients, both clinical pictures may have the same pathophysiology.

Entities:  

Keywords:  benign prostatic hyperplasia; erectile dysfunction; lower urinary tract symptoms

Year:  2013        PMID: 23904860      PMCID: PMC3721438          DOI: 10.1177/1756287213488236

Source DB:  PubMed          Journal:  Ther Adv Urol        ISSN: 1756-2872


  48 in total

Review 1.  A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.

Authors:  Mauro Gacci; Giovanni Corona; Matteo Salvi; Linda Vignozzi; Kevin T McVary; Steven A Kaplan; Claus G Roehrborn; Sergio Serni; Vincenzo Mirone; Marco Carini; Mario Maggi
Journal:  Eur Urol       Date:  2012-02-25       Impact factor: 20.096

2.  Increased corpus cavernosum smooth muscle tone associated with partial bladder outlet obstruction is mediated via Rho-kinase.

Authors:  Shaohua Chang; Joseph A Hypolite; Stephen A Zderic; Alan J Wein; Samuel Chacko; Michael E Disanto
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2005-06-16       Impact factor: 3.619

3.  Correlation between Lower Urinary Tract Symptoms (LUTS) and sexual function in benign prostatic hyperplasia: impact of treatment of LUTS on sexual function.

Authors:  Jae Hun Jung; Sung Uk Jae; Sung Chul Kam; Jae Seog Hyun
Journal:  J Sex Med       Date:  2009-06-02       Impact factor: 3.802

4.  Sacral neuromodulation for lower urinary tract dysfunction and impact on erectile function.

Authors:  Giuseppe Lombardi; Nicola Mondaini; Gianluca Giubilei; Angelo Macchiarella; Filippo Lecconi; Giulio Del Popolo
Journal:  J Sex Med       Date:  2008-07-15       Impact factor: 3.802

Review 5.  Age-related erectile and voiding dysfunction: the role of arterial insufficiency.

Authors:  T Tarcan; K M Azadzoi; M B Siroky; I Goldstein; R J Krane
Journal:  Br J Urol       Date:  1998-12

6.  Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms.

Authors:  Hanna Tinel; Beatrix Stelte-Ludwig; Joachim Hütter; Peter Sandner
Journal:  BJU Int       Date:  2006-09-06       Impact factor: 5.588

7.  Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction.

Authors:  R Jeroen A van Moorselaar; Rudolf Hartung; Mark Emberton; Niels Harving; Haim Matzkin; Mostafa Elhilali; Antonio Alcaraz; Guy Vallancien
Journal:  BJU Int       Date:  2005-03       Impact factor: 5.588

8.  Sexual dysfunction in the United States: prevalence and predictors.

Authors:  E O Laumann; A Paik; R C Rosen
Journal:  JAMA       Date:  1999-02-10       Impact factor: 56.272

9.  The associations among eNOS G894T gene polymorphism, erectile dysfunction, and benign prostate hyperplasia-related lower urinary tract symptoms.

Authors:  Yung-Chin Lee; Wen-Jeng Wu; Chia-Chu Liu; Chii-Jye Wang; Wei-Ming Li; Chun-Hsiung Huang; Hsin-Chih Yeh; Hung-Lung Ke; Shu-Pin Huang
Journal:  J Sex Med       Date:  2009-06-09       Impact factor: 3.802

10.  Lower urinary tract symptoms and erectile dysfunction are highly prevalent in ageing men.

Authors:  Sidney Glina; Antonio W Santana; Flavio Azank; Luiz F Mello; Edson D Moreira
Journal:  BJU Int       Date:  2006-04       Impact factor: 5.588

View more
  3 in total

1.  Current Diagnosis and Management of Erectile Dysfunction.

Authors:  Alexander W Pastuszak
Journal:  Curr Sex Health Rep       Date:  2014-09

Review 2.  Marijuana, Alcohol, and ED: Correlations with LUTS/BPH.

Authors:  Granville L Lloyd; Brett Wiesen; Mike Atwell; Anna Malykhina
Journal:  Curr Urol Rep       Date:  2021-02-08       Impact factor: 3.092

3.  Green & Sensitive pH-dependent Spectrofluorimetric Assay of Tamsulosin Hydrochloride and Tadalafil in their New Combined Formulation for Benign Prostatic Hyperplasia: Application to Spiked Human Plasma.

Authors:  Mona M Abdel Moneim
Journal:  J Fluoresc       Date:  2022-05-16       Impact factor: 2.525

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.